Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy

Susanne Vrtala, Kora Hirtenlehner, Luca Vangelista, Annalisa Pastore, Hans Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Rudolf Valenta

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational immunoglobulin E (IgE) epitopes on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by circular dichroism. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell epitopes and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.

Original languageEnglish
Pages (from-to)1673-1681
Number of pages9
JournalJournal of Clinical Investigation
Volume99
Issue number7
Publication statusPublished - Apr 1 1997
Externally publishedYes

Fingerprint

Betula
T-Lymphocyte Epitopes
Pollen
Immunotherapy
Allergens
T-Lymphocytes
Circular Dichroism
Immunoglobulin E
Epitopes
Complementary DNA
Clone Cells
Escherichia coli
Amino Acids

Keywords

  • Bet v 1
  • histamine release
  • major birch pollen allergen
  • recombinant allergen fragments
  • skin testing

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy. / Vrtala, Susanne; Hirtenlehner, Kora; Vangelista, Luca; Pastore, Annalisa; Eichler, Hans Georg; Sperr, Wolfgang R.; Valent, Peter; Ebner, Christof; Kraft, Dietrich; Valenta, Rudolf.

In: Journal of Clinical Investigation, Vol. 99, No. 7, 01.04.1997, p. 1673-1681.

Research output: Contribution to journalArticle

Vrtala, S, Hirtenlehner, K, Vangelista, L, Pastore, A, Eichler, HG, Sperr, WR, Valent, P, Ebner, C, Kraft, D & Valenta, R 1997, 'Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy', Journal of Clinical Investigation, vol. 99, no. 7, pp. 1673-1681.
Vrtala, Susanne ; Hirtenlehner, Kora ; Vangelista, Luca ; Pastore, Annalisa ; Eichler, Hans Georg ; Sperr, Wolfgang R. ; Valent, Peter ; Ebner, Christof ; Kraft, Dietrich ; Valenta, Rudolf. / Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy. In: Journal of Clinical Investigation. 1997 ; Vol. 99, No. 7. pp. 1673-1681.
@article{c130ad055dd74a2984254eae58b5350c,
title = "Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy",
abstract = "A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational immunoglobulin E (IgE) epitopes on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by circular dichroism. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell epitopes and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.",
keywords = "Bet v 1, histamine release, major birch pollen allergen, recombinant allergen fragments, skin testing",
author = "Susanne Vrtala and Kora Hirtenlehner and Luca Vangelista and Annalisa Pastore and Eichler, {Hans Georg} and Sperr, {Wolfgang R.} and Peter Valent and Christof Ebner and Dietrich Kraft and Rudolf Valenta",
year = "1997",
month = "4",
day = "1",
language = "English",
volume = "99",
pages = "1673--1681",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments. Candidates for a novel form of specific immunotherapy

AU - Vrtala, Susanne

AU - Hirtenlehner, Kora

AU - Vangelista, Luca

AU - Pastore, Annalisa

AU - Eichler, Hans Georg

AU - Sperr, Wolfgang R.

AU - Valent, Peter

AU - Ebner, Christof

AU - Kraft, Dietrich

AU - Valenta, Rudolf

PY - 1997/4/1

Y1 - 1997/4/1

N2 - A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational immunoglobulin E (IgE) epitopes on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by circular dichroism. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell epitopes and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.

AB - A novel approach to reduce the anaphylactic activity of allergens is suggested. The strategy makes use of the presence of conformational immunoglobulin E (IgE) epitopes on one of the most common allergens. The three dimensional structure of the major birch pollen allergen, Bet v 1, was disrupted by expressing two parts of the Bet v 1 cDNA representing amino acids 1-74 and 75-160 in Escherichia coli. In contrast to the complete recombinant Bet v 1, the fragments showed almost no allergenicity and exhibited random coil conformation as analyzed by circular dichroism. Both nonanaphylactic fragments induced proliferation of human Bet v 1-specific T cell clones, indicating that they harbored all dominant T cell epitopes and therefore may be considered as a basis for the development of a safe and specific T cell immunotherapy.

KW - Bet v 1

KW - histamine release

KW - major birch pollen allergen

KW - recombinant allergen fragments

KW - skin testing

UR - http://www.scopus.com/inward/record.url?scp=0030937231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030937231&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 1673

EP - 1681

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -